Antibiotic Resistance and What is ESG?

Podcast
18 min listen
Laura Nishikawa
December 17, 2021
In this episode

Antibiotic resistance is more worrisome than ever. It is possible that by 2050, three times as many people could die a year as died during the worst parts of the COVID-19 pandemic. But there may be hope in the development of novel antibiotics. We discuss how this is related to the development of the COVID-19 vaccine. Then we finally put ESG ratings in their rightful place and tell you what they are REALLY used for.
Listen
Spotify
Apple
YouTube
Transcript
Featuring
Laura Nishikawa
Laura Nishikawa
Managing Director, ESG Research
Julia Giguere-Morello, ESG Researcher, MSCI

Subscribe today
to have insights delivered to your inbox.

ESG Now Podcast

ESG explored. A rotating cast of researchers on environmental, social, and governance issues join hosts Mike Disabato and Bentley Kaplan as they discuss the most pressing news of the week. But in an enjoyable way.
Previous Episodes

2022 ESG Trends to Watch

Ten emerging trends for companies and investors.
Explore More

Putting ESG Ratings in Their Rightful Place

An ESG rating provides only one lens — a financial relevance lens that zooms in on questions of business resilience. That means answering other questions requires using other lenses.
Learn More

The content of this page is for informational purposes only and is intended for institutional professionals with the analytical resources and tools necessary to interpret any performance information. Nothing herein is intended to recommend any product, tool or service. For all references to laws, rules or regulations, please note that the information is provided “as is” and does not constitute legal advice or any binding interpretation. Any approach to comply with regulatory or policy initiatives should be discussed with your own legal counsel and/or the relevant competent authority, as needed.